Monogram Announces Presentation Of Clinical Data For The HERmark? Breast Cancer Assay

[News]

Monogram Biosciences, Inc. (Nasdaq:MGRM) announced that new results from a study of the predictive power of its HERmark? Breast Cancer Assay were presented at the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas. An oral presentation, entitled "HER2 Protein expression and homodimer levels predict response to trastuzumab in centrally tested FISH-positive metastatic breast cancer patients", was made by Allan Lipton M.D.

More... (http://www.medicalnewstoday.com/articles/133042.php)